Skip to main content
Journal cover image

Phase II study of two-weekly temozolomide in patients with high-grade gliomas.

Publication ,  Journal Article
Wong, S; Rosenthal, MA; Dowling, A; Jennens, R; Woods, A-M; Ashley, D; Cher, L
Published in: J Clin Neurosci
January 2006

Palliative chemotherapy has an increasing role in the management of recurrent high-grade gliomas. Temozolomide is a well-tolerated agent that results in objective responses and stabilisation of disease. Theoretically, temozolomide may be more effective when given in a prolonged schedule rather than the standard 5 days-monthly schedule. This Phase II study examined the efficacy and toxicity of temozolomide when given in a two-weekly schedule. Twenty-five patients received 150 mg/m2 temozolomide daily for seven days alternating with seven days of no treatment. One cycle of temozolomide was a total of two weeks treatment in every 28 days. Of the 25 evaluable patients, there was one complete response (4%), four partial responses (16%) and 10 patients had disease stablisation (40%). The progression free survival at 6 months was 56%. Two-weekly temozolomide was well tolerated with only four episodes of Grade 3 thrombocytopenia. Overall, two-weekly temozolomide is an active and well tolerated schedule, but does not appear to improve on the activity of temozolomide using the standard 5-day schedule.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Neurosci

DOI

ISSN

0967-5868

Publication Date

January 2006

Volume

13

Issue

1

Start / End Page

18 / 22

Location

Scotland

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Temozolomide
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Humans
  • Glioma
  • Female
  • Drug Evaluation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wong, S., Rosenthal, M. A., Dowling, A., Jennens, R., Woods, A.-M., Ashley, D., & Cher, L. (2006). Phase II study of two-weekly temozolomide in patients with high-grade gliomas. J Clin Neurosci, 13(1), 18–22. https://doi.org/10.1016/j.jocn.2004.10.018
Wong, Shirley, Mark A. Rosenthal, Anthony Dowling, Ross Jennens, Anne-Marie Woods, David Ashley, and Lawrence Cher. “Phase II study of two-weekly temozolomide in patients with high-grade gliomas.J Clin Neurosci 13, no. 1 (January 2006): 18–22. https://doi.org/10.1016/j.jocn.2004.10.018.
Wong S, Rosenthal MA, Dowling A, Jennens R, Woods A-M, Ashley D, et al. Phase II study of two-weekly temozolomide in patients with high-grade gliomas. J Clin Neurosci. 2006 Jan;13(1):18–22.
Wong, Shirley, et al. “Phase II study of two-weekly temozolomide in patients with high-grade gliomas.J Clin Neurosci, vol. 13, no. 1, Jan. 2006, pp. 18–22. Pubmed, doi:10.1016/j.jocn.2004.10.018.
Wong S, Rosenthal MA, Dowling A, Jennens R, Woods A-M, Ashley D, Cher L. Phase II study of two-weekly temozolomide in patients with high-grade gliomas. J Clin Neurosci. 2006 Jan;13(1):18–22.
Journal cover image

Published In

J Clin Neurosci

DOI

ISSN

0967-5868

Publication Date

January 2006

Volume

13

Issue

1

Start / End Page

18 / 22

Location

Scotland

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Temozolomide
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Humans
  • Glioma
  • Female
  • Drug Evaluation